MVIS US Listed Pharmaceutical 25 Index
The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that derive at least 50% of their revenues from pharmaceuticals. The pure-play index contains only companies which are engaged primarily engaged in research (incl. research contractors) and development as well as production, marketing and sales of pharmaceuticals. Pharmacies are excluded. The MVIS US Listed Pharmaceutical 25 Index (MVPPH) has been licensed to underlie financial products with currently USD 261.7 million in assets under management.
Country and Sector Weightings
MVIS Sector Indices are pure-play sector indices. Companies must generate at least 50% of their revenues in the target sector to be eligible for index inclusion. Country and Sector weightings are based on the weightings of all index components in a certain country or sector.
| Country | Components | Weight |
| Canada | 1 | 2.78% |
| United States | 13 | 56.39% |
| Denmark | 1 | 4.78% |
| France | 1 | 4.68% |
| Ireland | 2 | 6.43% |
| Switzerland | 1 | 4.87% |
| United Kingdom | 4 | 11.05% |
| Israel | 1 | 4.76% |
| Japan | 1 | 4.25% |
| Total | 25 | 100.00% |
| Sector | Components | Weight |
| Health Care | 25 | 100.00% |
| Total | 25 | 100.00% |
Size Weightings
- Large-Cap: companies with a market capitalisation above 6,000 mln USD
- Mid-Cap: companies with a market capitalisation from 1,500 mln to 6,000 mln USD
- Small-Cap: companies with a market capitalisation from 200 mln to 1,500 mln USD
- Micro-Cap: companies with a market capitalisation up to 200 mln USD
| Size | Market Cap | Components | Weight |
| Large-Cap | 2,210,655,042,500 USD | 22 | 97.03% |
| Mid-Cap | 8,385,391,400 USD | 3 | 2.97% |
| Small-Cap | - | - | - |
| Micro-Cap | - | - | - |
| Total | 2,219,040,433,900 USD | 25 | 100.00% |
